Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C9 | P11712 | 4/20 | 0.53 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.53 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.53 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 2/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | MMP13 | P45452 | 1/20 | 0.36 |
| ▸ | NPC1 | O15118 | 2/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | TP53 | P04637 | 1/20 | 0.36 |
| ▸ | ATM | Q13315 | 1/20 | 0.36 |
| ▸ | CCR1 | P32246 | 1/20 | 0.35 |
| ▸ | TSPO | P30536 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13838114 | 0.87 | CYP2C9 (0.70) | CYP2C9CYP2C19CYP3A4MEN1KMT2A | |
| SCHEMBL12295250 | 0.82 | CYP2C9 (0.77) | CYP2C9CYP2C19CYP3A4CYP1A2POLB | |
| SCHEMBL17590084 | 0.82 | CYP2C9 (0.50) | CYP2C9CYP2C19CYP3A4POLBALDH1A1 | |
| SCHEMBL16447431 | 0.81 | CYP2C9 (0.70) | CYP2C9CYP2C19CYP3A4CYP1A2POLB | |
| SCHEMBL12296306 | 0.77 | MEN1 (0.47) | CYP2C9CYP2C19CYP1A2ALDH1A1GAA | |
| SCHEMBL12295308 | 0.75 | CYP2C9 (0.69) | CYP2C9CYP2C19CYP3A4CYP1A2POLB | |
| SCHEMBL17590115 | 0.75 | CYP2C9 (0.48) | CYP2C9CYP2C19CYP3A4ALDH1A1MEN1 | |
| SCHEMBL12294658 | 0.74 | CYP2C9 (0.73) | CYP2C9CYP2C19CYP3A4CYP1A2POLB | |
| SCHEMBL12295306 | 0.74 | CYP2C9 (0.53) | CYP2C9CYP2C19CYP3A4CYP1A2POLB | |
| SCHEMBL12296310 | 0.73 | CYP2C9 (0.66) | CYP2C9CYP2C19CYP3A4CYP1A2POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9029389-B2 | Anti-inflammation compounds | INSTITUT PASTEUR KOREA (KR) | 2015-05-12 | — | — | US | claimed |
| US-8865734-B2 | Anti-infective compounds | INSTITUT PASTEUR KOREA (KR) | 2014-10-21 | — | — | US | claimed |
| EP-2547678-B1 | ANTI-INFECTIVE COMPOUNDS | PASTEUR INSTITUT KOREA (KR) | 2016-03-16 | — | — | EP | disclosed |
| EP-2547678-B1 | ANTI-INFECTIVE COMPOUNDS | PASTEUR INSTITUT KOREA (KR) | 2016-03-16 | — | — | EP | disclosed |
| US-9029389-B2 | Anti-inflammation compounds | INSTITUT PASTEUR KOREA (KR) | 2015-05-12 | — | — | US | disclosed |
| US-9029389-B2 | Anti-inflammation compounds | INSTITUT PASTEUR KOREA (KR) | 2015-05-12 | — | — | US | disclosed |
| US-9029389-B2 | Anti-inflammation compounds | INSTITUT PASTEUR KOREA (KR) | 2015-05-12 | — | — | US | disclosed |
| US-8865734-B2 | Anti-infective compounds | INSTITUT PASTEUR KOREA (KR) | 2014-10-21 | — | — | US | disclosed |
| US-8865734-B2 | Anti-infective compounds | INSTITUT PASTEUR KOREA (KR) | 2014-10-21 | — | — | US | disclosed |
| US-8865734-B2 | Anti-infective compounds | INSTITUT PASTEUR KOREA (KR) | 2014-10-21 | — | — | US | disclosed |
| US-20140155387-A1 | Anti-Inflammation Compounds | QURIENT, CO. LTD. (KR) | 2014-06-05 | — | — | US | disclosed |
| US-20140155387-A1 | Anti-Inflammation Compounds | QURIENT, CO. LTD. (KR) | 2014-06-05 | — | — | US | disclosed |
| US-20140155387-A1 | Anti-Inflammation Compounds | QURIENT, CO. LTD. (KR) | 2014-06-05 | — | — | US | disclosed |
| US-20130065884-A1 | Anti-Infective Compounds | INSTITUT PASTEUR KOREA (KR) | 2013-03-14 | — | — | US | disclosed |
| US-20130065884-A1 | Anti-Infective Compounds | INSTITUT PASTEUR KOREA (KR) | 2013-03-14 | — | — | US | disclosed |
| US-20130065884-A1 | Anti-Infective Compounds | INSTITUT PASTEUR KOREA (KR) | 2013-03-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130065884-A1 | Anti-Infective Compounds | RABGGTB, ELANE, SERPINB1 | CYP2C9 4235/4885CYP2C19 4181/4885CYP3A4 2915/4885 |
| US-20140155387-A1 | Anti-Inflammation Compounds | NR0B1, NR0B2, NR5A2 | CYP2C9 1210/4885CYP2C19 2085/4885CYP3A4 366/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.